Imviva Biotech Achieves 100% SRI-4 Response Rate in Phase 1/2 CTA313 Lupus Study

Allogeneic CAR-T manufacturing is moving closer to the clinic, and Imviva Biotech's Phase 1/2 data for CTA313 in systemic lupus erythematosus signals that donor-derived cell therapy programs are generating outcomes that will accelerate regulatory and GMP scrutiny. Presented at ASGCT 2026 in Boston, the data from 18 evaluable patients showed a 100% SRI-4 response rate and 50% DORIS remission in a mixed SLE/lupus nephritis cohort at a median six-month follow-up.

In the non-renal SLE sub-cohort, 80% of patients achieved DORIS remission, with 90% of those reaching immunosuppression-free remission. Anti-dsDNA autoantibody clearance was sustained below detectable levels for 12 months, consistent with the proposed immune-reset mechanism: deep B-cell depletion followed by reconstitution of a predominantly naïve, non-autoimmune B-cell repertoire.

For plant heads and QA directors, the manufacturing profile of CTA313 carries direct operational weight. The product is derived from healthy donors, incorporates proprietary ANSWER™ inhibitory ligands, and includes genetic edits designed to resist host immune rejection. That combination places CTA313 squarely within the evolving GMP framework for allogeneic cell therapies, where batch consistency, genetic editing controls, and release testing for donor-derived starting material remain active areas of regulatory development. Off-the-shelf storage capability adds a further layer of cold-chain and shelf-life validation requirements that quality teams should be mapping now.

CTA313 has been evaluated across multiple autoimmune indications in China, including systemic sclerosis, ANCA-associated vasculitis, and idiopathic inflammatory myopathy, alongside SLE and lupus nephritis. The breadth of indications under a single Phase 1/2 protocol raises questions about comparability of manufacturing lots across cohorts, a consideration that will bear on any future process validation strategy aligned with ICH Q10 principles.

Current standard-of-care for SLE relies on broad immunosuppression and carries well-documented risks of incomplete response and long-term toxicity. The clinical signal from CTA313 positions allogeneic CAR-T as a mechanistically distinct alternative, but the path from these early data to a validated commercial manufacturing process will require rigorous attention to donor qualification, genetic edit characterisation, and potency assay development.

The next measurable checkpoint is extended follow-up data beyond the 12-month anti-dsDNA clearance window already reported, which will be critical for establishing the durability claims that any future BLA or IND-enabling package will need to support.

Source: Imviva Biotech via GlobeNewswire, 14 May 2026.